At a glance
- Originator Merck & Co
- Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 03 Nov 2005 No development reported - Preclinical for Obesity in USA (unspecified route)
- 13 Mar 2002 Preclinical trials in Obesity in USA (unspecified route)